Yahoo Finance

Operations: PharmaCyte Biotech, Inc. does not report any specific revenue segments.

Market Cap: $11.57M

PharmaCyte Biotech, Inc., with a market cap of US$11.57 million, is a pre-revenue biotech firm focusing on cellular therapies for cancer. The company recently reported a significant one-off gain of US$15.9 million, which impacted its financial results for the year ending October 31, 2024. Despite this, it has become profitable over the past year and maintains an outstanding return on equity of 52.2%. With no debt and stable weekly volatility at 8%, PharmaCyte's short-term assets (US$21.3 million) comfortably cover both short-term (US$4.8 million) and long-term liabilities (US$6.9 million).

• Get an in-depth perspective on PharmaCyte Biotech's performance by reading our balance sheet health report here.

• Evaluate PharmaCyte Biotech's historical performance by accessing our past performance report.

Vaso

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vaso Corporation, along with its subsidiaries, operates in the healthcare equipment and information technology sectors both domestically and internationally, with a market cap of $22.82 million.

Operations: The company generates revenue from three main segments: IT ($41.62 million), Equipment ($2.26 million), and Professional Sales Service ($37.77 million).

Market Cap: $22.82M

Vaso Corporation, with a market cap of US$22.82 million, operates in the healthcare equipment and IT sectors. Despite being unprofitable, it has significantly reduced its losses over the past five years. The company benefits from a seasoned board with an average tenure of 14 years and an experienced management team. Vaso's financial stability is evident as its short-term assets (US$43 million) exceed both short-term (US$30.2 million) and long-term liabilities (US$18.1 million). Recent executive changes include Edgar Rios as Vice Chairman and Jane Moen as Chief Operating Officer, indicating strategic leadership adjustments for future growth.

• Unlock comprehensive insights into our analysis of Vaso stock in this financial health report.

• Examine Vaso's past performance report to understand how it has performed in prior years.

Taking Advantage

• Access the full spectrum of 735 US Penny Stocks by clicking on this link.

• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.

• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Jump on the AI train with fast growing tech companies forging a new era of innovation.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:PETZ NasdaqCM:PMCB and OTCPK:VASO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com